Bobby Soni

Bobby Soni has extensive work experience in the biotechnology and pharmaceutical industry. Bobby is currently serving as the Chief Business Officer at BioInnovation Institute, where they lead the incubation, acceleration, and funding of life science companies. Prior to this, Bobby has held various positions such as Board Observer at Breye Therapeutics ApS and Twelve Bio. Bobby has also served as a Non Executive Director at STORM Therapeutics Limited, Mission Therapeutics, Autifony Therapeutics, PULMOCIDE LIMITED, IP Group plc, Artios Pharma Ltd, and Enterprise Therapeutics. Bobby's roles have involved strategic decision-making, collaboration agreements, and the development of novel therapies for cancer, CNS diseases, and respiratory conditions.

Bobby Soni earned their Bachelor of Science degree in Biochemistry from the University of Rochester in 1992. Bobby went on to pursue their PhD in Biology at the University of Virginia from 1992 to 1998. During their PhD studies, Bobby Soni also served as a visiting PhD student at Imperial College London from 1995 to 1998.

In 2009, Bobby Soni participated in an executive education program on Venture Capital and Private Equity at Harvard Business School. Bobby further enhanced their skills in 2011 by attending the High Performance People Skills program at the London Business School.